Screener
Nektar Therapeutics NKTR Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
|---|---|---|---|
| Non-operating income (expense): | |||
| Non-cash interest expense on liabilities related to the sales of future royalties | (7,942) | (4,974) | |
| Interest income | 4,242 | 2,874 | |
| Other income (expense), net (including income of $2 and $321 for the three months ended March 31, 2026 and 2025, respectively, from a related party) | (336) | 266 | |
| Total non-operating income (expense), net | (4,036) | (1,834) | |
| Loss before provision for income taxes and equity method investment | (43,090) | (46,369) | |
| Provision for income taxes | 64 | 52 | |
| Loss before equity method investment | (43,154) | (46,421) |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's other income, net (note 6)?
- Nektar Therapeutics (NKTR) reported other income, net (note 6) of -$336K in Q1 2026.
- How has Nektar Therapeutics's other income, net (note 6) changed year-over-year?
- Nektar Therapeutics's other income, net (note 6) decreased by 226.3% year-over-year, from $266K to -$336K.
- What is the long-term trend for Nektar Therapeutics's other income, net (note 6)?
- Over 3 years (2021 to 2024), Nektar Therapeutics's other income, net (note 6) has grown at a 34.0% compound annual growth rate (CAGR), from -$162K to -$390K.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Nektar Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude